Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Kieran Brennan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomolecular and Biomedical Science, University College Dublin (UCD), Dublin, Ireland. Hauptthemen laut MEDLINE: Multiple Myeloma, Extracellular Vesicles, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCD Wellcome Institutional Strategic Support Fund, TwinFlag consortium, Holms Mindelegat.
Abstract (Originalsprache)
Daratumumab (DARA) is a human monoclonal antibody for the treatment of multiple myeloma (MM), an incurable hematologic malignancy characterised by the accumulation of malignant plasma cells, located in the bone marrow (BM). We previously reported that peripheral blood plasma (PB) extracellular vesicles (EVs), isolated from 57 MM patients treated with DARA contain elevated CD55, CD59 and CD147 relative to healthy PB EVs, and elevated PDL1 was associated with patient response to DARA. The aim of this study was to identify additional proteins altered in these patients in order to generate predictive MM EV protein signatures. Flow cytometry analysis revealed that CD31, CD36 and CD44 were significantly elevated in MM PB EVs relative to healthy PB EVs, while CD8 and LAT1 were significantly decreased. CD38, LAT1 and PDL1 were significantly higher in PB EVs of patients with a long‐term response to DARA. Multivariate ROC curves revealed a diagnostic signature (MM panel) with a sensitivity 86.4% and specificity 91.6%, and a predictive signature (Response panel) with a sensitivity 80% and specificity 91.2%. In conclusion we identified two EV signatures that may have potential as a non‐invasive liquid biopsy to complement or replace invasive BM sampling for monitoring patient response to DARA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomolecular and Biomedical Science, University College Dublin (UCD), Dublin, Ireland.
- Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD), Dublin, Ireland.
- Institute of Regional Health Science, University of Southern Denmark, Vejle, Denmark.
- Department of Internal Medicine, Section of Hematology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
- Flow Cytometry Core Technology, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD), Dublin, Ireland.
- Centre for Innovative Medical Technology, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Kieran Brennan, Katrine F Iversen, Alfonso Blanco-Fernández, Thomas Lund, Torben Plesner, Margaret M Mc Gee
Förderung
- UCD Wellcome Institutional Strategic Support Fund
- TwinFlag consortium
- Holms Mindelegat
- The Region of Southern Denmark
- Dagmar Marshalls Fond
- Science Foundation Ireland Research Infrastructure Programme
- UCD Equip Funding Programme
Zitieren
APA
Brennan, K., Iversen, K. F., Blanco-Fernández, A., Lund, T., Plesner, T., & Mc Gee, M. M. (2026). Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70213
Vancouver
Brennan K, Iversen KF, Blanco-Fernández A, Lund T, Plesner T, Mc Gee MM. Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70213
BibTeX
@article{Brennan2026,
author = {Brennan, Kieran and Iversen, Katrine F and Blanco-Fernández, Alfonso and Lund, Thomas and Plesner, Torben and Mc Gee, Margaret M},
title = {Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70213}
}
EUVIMED